EyePoint, Inc.
EyePoint, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Laboratory Analytical Instruments.
The next scheduled catalyst is A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 on October 15, 2026. There are 4 upcoming events on record.
Cash runway is approximately 6.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 15 concluded trials, 67% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 15, 2026 | A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 | Trial Milestone | Phase 3 |
| December 9, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| October 15, 2027 | CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | Trial Milestone | Phase 3 |
| October 15, 2027 | COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | Trial Milestone | Phase 3 |
Track EYPT alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open EYPT in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.